-- WSP Global (WSP.TO) 周三盘后发布财报称,其第一季度营收和利润均同比增长,超出预期。 该公司表示,经调整后的净利润(不计大部分一次性项目)同比增长30%至2.977亿加元,合每股2.21加元,高于去年同期的2.291亿加元(合每股1.76加元)。FactSet此前预期每股收益为2.06加元。 营收同比增长3.7%至45.5亿美元,高于去年同期的43.9亿美元。FactSet此前预期为36.8亿美元。 WSP表示,截至3月27日,其积压订单额达到创纪录的197亿美元,同比增长19%,相当于11.5个月的营收。本季度调整后 EBITDA 增长至 6.222 亿美元,而 2025 年第一季度为 5.339 亿美元,增幅达 16.5%。 该公司预计 2026 年净收入将在 160 亿美元至 170 亿美元之间,高于 2025 年的 139.6 亿美元。 WSP 董事会宣布派发每股 0.375 美元的股息,将于 7 月 15 日左右支付给截至 6 月 30 日营业结束时登记在册的股东。 “我们的积压订单和在建项目依然非常活跃,凸显了我们全球多元化平台的实力。我们很高兴完成了对 TRC 的收购,这是高增长领域中一个极具战略意义且恰逢其时的里程碑,整合工作正按计划进行。展望未来,我们对市场机遇充满信心,并将继续专注于价值创造,”首席执行官 Alexandre L'Heureux 表示。 WSP股票在多伦多证券交易所收盘下跌3.87美元,至225.72美元。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.